Reyes M, Rojas-Alcayaga G, Maturana A, Aitken JP, Rojas C, Ortega AV. Increased nuclear β-catenin expression in oral potentially malignant lesions: A marker of epithelial dysplasia. Med Oral Patol Oral Cir Bucal. 2015 Sep 1;20 (5):e540-6.  

 

 

doi:10.4317/medoral.20341

http://dx.doi.org/doi:10.4317/medoral.20341

 

 

1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80.
http://dx.doi.org/10.1111/j.1600-0714.2007.00582.x

 

2. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008;37:127-33.
http://dx.doi.org/10.1111/j.1600-0714.2007.00584.x

 

3. Reichart PA, Philipsen HP. Oral erythroplakia-a review. Oral Oncol. 2005;41:551-61.
http://dx.doi.org/10.1016/j.oraloncology.2004.12.003

 

4. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215.
http://dx.doi.org/10.3322/canjclin.52.4.195

 

5. Hall GL, Shaw RJ, Field EA, Rogers SN, Sutton DN, Woolgar JA, et al. p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev. 2008;17:2174-9.
http://dx.doi.org/10.1158/1055-9965.EPI-07-2867

 

6. Krutchkoff DJ, Eisenberg E, Anderson C. Dysplasia of oral mucosa: a unified approach to proper evaluation. Mod Pathol. 1991;4:113-9.

 

7. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst. 1990;82:555-60.
http://dx.doi.org/10.1093/jnci/82.7.555

 

8. Kushner J, Bradley G, Jordan RC. Patterns of p53 and Ki-67 protein expression in epithelial dysplasia from the floor of the mouth. J Pathol. 1997;183:418-23.
http://dx.doi.org/10.1002/(SICI)1096-9896(199712)183:4<418::AID-PATH946>3.0.CO;2-T

 

9. Zoeller J, Flentje M, Sinn P, Born IA. Evaluation of AgNOR and Ki-67 antigen as cell kinetic parameters in oral dysplasias and carcinomas. Anal Cell Pathol. 1994;7:77-88.

 

10. Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R, et al. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol. 2014;50:168-77.
http://dx.doi.org/10.1016/j.oraloncology.2013.12.008

 

11. Zidar N, Gale N, Cor A, Kambic V. Expression of Ki-67 antigen and proliferative cell nuclear antigen in benign and malignant epithelial lesions of the larynx. J Laryngol Otol. 1996;110:440-5.
http://dx.doi.org/10.1017/S0022215100133924

 

12. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99-109.
http://dx.doi.org/10.1016/0092-8674(82)90409-3

 

13. KŸhl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 2000;16:279-83.
http://dx.doi.org/10.1016/S0168-9525(00)02028-X

 

14. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J. 1998;329:209-23.
http://dx.doi.org/10.1042/bj3290209

 

15. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A. 1995;92:3046-50.
http://dx.doi.org/10.1073/pnas.92.7.3046

 

16. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem. 1997;272:24735-8.
http://dx.doi.org/10.1074/jbc.272.40.24735

 

17. Takahashi-Yanaga F, Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci. 2007;104:293-302.
http://dx.doi.org/10.1254/jphs.CR0070024

 

18. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-50.
http://dx.doi.org/10.1038/nature03319

 

19. Ochoa-Hernandez AB, Juarez-Vazquez CI, Rosales-Reynoso MA, Barros-Nunez P. [WNT-beta-catenin signaling pathway and its relationship with cancer]. Cir Cir. 2012;80:389-98.

 

20. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004;4:653-71.
http://dx.doi.org/10.2174/1568009043332709

 

21. Gonzalez-Moles MA, Ruiz-Avila I, Gil-Montoya JA, Esteban F, Bravo M. Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral Oncol. 2010;46:525-30.
http://dx.doi.org/10.1016/j.oraloncology.2010.03.020

 

22. Warnakulasuriya KA, MacDonald DG. Epithelial cell kinetics in oral leukoplakia. J Oral Pathol Med. 1995;24:165-9.
http://dx.doi.org/10.1111/j.1600-0714.1995.tb01159.x

 

23. Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Shah JS, Jetly DH, et al. Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers. 2007;22:132-43.

 

24. Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol. 1999;154:613-22.
http://dx.doi.org/10.1016/S0002-9440(10)65306-0

 

25. Saito T, Nakajima T, Mogi K. Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas. J Oral Pathol Med. 1999;28:226-32.
http://dx.doi.org/10.1111/j.1600-0714.1999.tb02029.x

 

26. Mimica M, Tomic S, Kardum G, Hofman ID, Kaliterna V, Pejkovic L. Ki-67 quantitative evaluation as a marker of cervical intraepithelial neoplasia and human papillomavirus infection. Int J Gynecol Cancer. 2010;20:116-9.
http://dx.doi.org/10.1111/IGC.0b013e3181bc8da7

 

27. Cambruzzi E, Zettler CG, Alexandre CO. Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res. 2005;11:114-20.
http://dx.doi.org/10.1007/BF02893378

 

28. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997;13:119-46.
http://dx.doi.org/10.1146/annurev.cellbio.13.1.119

 

29. Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord. 2006;7:41-9.
http://dx.doi.org/10.1007/s11154-006-9003-3

 

30. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810.
http://dx.doi.org/10.1146/annurev.cellbio.20.010403.113126

 

31. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, et al. Wnt signaling and human diseases: what are the therapeutic implications?. Lab Invest. 2007;87:97-103.
http://dx.doi.org/10.1038/labinvest.3700509

 

32. Lo Muzio L, Lo Russo L, Falaschini S, Ciavarella D, Pentenero M, Arduino P, et al. beta- and gamma-catenin expression in oral dysplasia. Oral Oncol. 2009;45:501-4.
http://dx.doi.org/10.1016/j.oraloncology.2008.06.004

 

33. Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C. Aberrant beta-catenin expression in the histologic differentiation of oral squamous cell carcinoma and verrucous carcinoma: an immunohistochemical study. J Oral Sci. 2010;52:633-40.
http://dx.doi.org/10.2334/josnusd.52.633

 

34. Williams HK, Sanders DS, Jankowski JA, Landini G, Brown AM. Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med. 1998;27:308-17.
http://dx.doi.org/10.1111/j.1600-0714.1998.tb01962.x

 

35. Bankfalvi A, Krassort M, Vegh A, Felszeghy E, Piffko J. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med. 2002;31:450-7.
http://dx.doi.org/10.1034/j.1600-0714.2002.00147.x

 

36. Bankfalvi A, Krassort M, Buchwalow IB, Vegh A, Felszeghy E, Piffko J. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol. 2002;198:343-51.
http://dx.doi.org/10.1002/path.1204

 

37. Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, et al. beta-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res. 2005;11:2471-7.
http://dx.doi.org/10.1158/1078-0432.CCR-04-2199

 

38. Gasparoni A, Chaves A, Fonzi L, Johnson GK, Schneider GB, Squier CA. Subcellular localization of beta-catenin in malignant cell lines and squamous cell carcinomas of the oral cavity. J Oral Pathol Med. 2002;31:385-94.
http://dx.doi.org/10.1034/j.1600-0714.2002.00108.x

 

39. Bagutti C, Speight PM, Watt FM. Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. J Pathol. 1998;186:8-16.
http://dx.doi.org/10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H

 

40. Sato K, Okazaki Y, Tonogi M, Tanaka Y, Yamane GY. Expression of beta-catenin in rat oral epithelial dysplasia induced by 4-nitroquinoline 1-oxide. Oral Oncol. 2002;38:772-8.
http://dx.doi.org/10.1016/S1368-8375(02)00044-1

 

41. Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, et al. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer. 2007;6:62.
http://dx.doi.org/10.1186/1476-4598-6-62